Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2013

View Archived Issues

Researchers discover novel urinary biomarker of membranous nephropathy

Investigators present preclinical data for (+)-[18F]flubatine

Tigatuzumab evaluated in patients with triple-negative breast cancer

First-in-human data for SYK inhibitor P505-15

Faldaprevir/BI-207127/ribavirin HCV treatment regimen analyzed in phase II trial

Novel PKB/c-Akt inhibitors synthesized by Array BioPharma and Genentech

Biosortia collaborates to discover natural products for infectious disease

Sea Lane grants Takeda access to ConCIRT libraries for use in drug discovery

First patient enrolled in global phase IIb study of rostafuroxin

Ataluren demonstrates sustained effects over time in patients with nmCF

Amrita Therapeutics discloses novel antiviral proteins

Nerviano Medical Sciences presents new PARP inhibitors

New PKC-iota inhibitors synthesized at Cancer Research Technology and Cephalon

Verastem receives orphan medicinal product designation in Europe for VS-6063

Omeros cleared to begin phase I trial of OMS-721

Bionor Pharma completes first part of phase II study combining Vacc-4x with Revlimid

Epizyme enrolls first patient in phase I/II trial of EPZ-6438

Northwest Biotherapeutics begins phase I/II trial of DCVax-Direct in solid tumors

Lilly's BACC study in Alzheimer's disease terminated

Xoma begins pilot trial of gevokizumab in patients with pyoderma gangrenosum

Safety monitoring board recommends continuation of VALOR trial

FDA approves Xgeva to treat giant cell tumor of bone

Cangene withdraws IB-1001 MAA, plans to resubmit

Astellas launches Xtandi in Canada for castration-resistant prostate cancer

First phase II results of novel cPLA2 inhibitor for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...